AllakosALLK
About: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Employees: 131
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3,000% more call options, than puts
Call options by funds: $31K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
11.59% less ownership
Funds ownership: 90.66% [Q2] → 79.07% (-11.59%) [Q3]
22% less funds holding
Funds holding: 100 [Q2] → 78 (-22) [Q3]
43% less capital invested
Capital invested by funds: $80.3M [Q2] → $45.9M (-$34.4M) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 26
69% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 32
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JMP Securities Jonathan Wolleben 51% 1-year accuracy 35 / 69 met price target | 186%upside $3 | Market Outperform Reiterated | 26 Sept 2024 |